|
Eucalyptus gum
|
DB15537 |
|
|
Ferric chloride
|
DB15536 |
|
|
Cobaltous cation
|
DB14205 |
|
|
Silk sericin
|
DB15531 |
|
|
Thiohexam
|
DB14200 |
[Thiohexam is a rubber cure accelerator. It is also a known allergen and dermatological sensitizer.
Sensitivity to Thiohexam may be identified with a clinical patch test.] |
|
Trifolium pratense pollen
|
DB15530 |
[Trifolium pratense pollen allergenic extract is used in allergenic testing.] |
|
Morpholinylmercaptobenzothiazole
|
DB14202 |
|
|
Calcium sulfate
|
DB15533 |
|
|
Madecassoside
|
DB15532 |
|
|
2,2'-Dibenzothiazyl disulfide
|
DB14201 |
[2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer.
Sensitivity to 2,2'-Dibenzothiazyl disulfide may be identified with a clinical patch test.] |
|
Cyclohexylformamide
|
DB03559 |
|
|
2-deoxy-2-fluoro-β-D-galactose
|
DB02228 |
|
|
5'-O-[(L-methionyl)-sulphamoyl]adenosine
|
DB02229 |
|
|
Bicifadine
|
DB04889 |
[Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.] |
|
3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium
|
DB02226 |
|
|
4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid
|
DB03557 |
|
|
SP-876
|
DB03558 |
|
|
4,5-Dihydroxy-Tetrahydro-Pyran-2-Carboxylic Acid
|
DB02227 |
|
|
Bifeprunox
|
DB04888 |
[Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.] |
|
Brecanavir
|
DB04887 |
[Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.] |
